News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins Caitlin E. Cox November 14, 2017
Presentation AHA 2017 Subgroup Analysis from the RE-DUAL PCI Trial Presenter: Jonas Oldgren November 14, 2017
News Industry News New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery November 14, 2017
News Conference News AHA 2017 DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy Yael L. Maxwell November 12, 2017
News Conference News AHA 2017 Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List Michael O'Riordan November 12, 2017
Presentation AHA 2017 One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study Presenter: Zuzana Motovska November 11, 2017
News Daily News New Performance and Quality Metrics for STEMI and NSTEMI Care Michael O'Riordan September 21, 2017
News Features How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts Michael O'Riordan May 23, 2017
News Daily News $2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor Michael O'Riordan May 12, 2017
News Daily News ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events Michael O'Riordan April 04, 2017
News Conference News AHA 2016 Proton Pump Inhibitor Use Tied to Elevated Ischemic Stroke Risk Todd Neale November 16, 2016
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Conference News AHA 2016 Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients Yael L. Maxwell November 13, 2016
News Daily News High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients Michael O'Riordan November 10, 2016
News Daily News El Tratamiento con Estatinas de Alta Intensidad Ofrece una Mayor Supervivencia sobre las Estatinas de Intensidad Moderada en Pacientes con Enfermedad Cardiovascular Michael O'Riordan November 10, 2016
News Daily News Newest Atherosclerosis Risk Calculator Aims to Adjust Predictions as Prevention Tactics Kick In Yael L. Maxwell November 10, 2016